hydroxychloroquine and everolimus

hydroxychloroquine has been researched along with everolimus in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (80.00)	24.3611
2020's	1 (20.00)	2.80

Authors

Authors	Studies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Digumarthy, S; Fidias, P; Goldberg, SB; Heist, RS; Lynch, TJ; McCarthy, PO; Muzikansky, A; Neal, JW; Sequist, LV; Settleman, JE; Sharma, S; Shaw, AT; Supko, JG; Temel, JS	1
Hudes, GR; Kruger, WD; Lee, HO; Mustafa, A	1
Amaravadi, RK; Appleman, LJ; Davis, LE; Gimotty, PA; Haas, NB; Kadri, S; Kalavacharla, A; Kim, T; Onorati, A; Redlinger, M; Segal, JP; Stein, M; Wilks, M; Xu, X; Zhen, CJ	1
Chen, S; Ji, Y; Luo, M; Wang, Q; Xiang, B	1

Reviews

2 review(s) available for hydroxychloroquine and everolimus

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis. Respiratory research, 2020, Feb-14, Volume: 21, Issue:1 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Everolimus; Humans; Hydroxychloroquine; Hyperlipidemias; Lymphangioleiomyomatosis; Prospective Studies; Sirolimus; Stomatitis; Treatment Outcome	2020

Article

Year

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.

Drug discovery today, 2016, Volume: 21, Issue:4

Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis.

Respiratory research, 2020, Feb-14, Volume: 21, Issue:1

Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Everolimus; Humans; Hydroxychloroquine; Hyperlipidemias; Lymphangioleiomyomatosis; Prospective Studies; Sirolimus; Stomatitis; Treatment Outcome

2020

Trials

2 trial(s) available for hydroxychloroquine and everolimus

Article	Year
A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Everolimus; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Sirolimus; Tissue Distribution	2012
Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 04-01, Volume: 25, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Renal Cell; Everolimus; Female; Humans; Hydroxychloroquine; Kidney Neoplasms; Male; Middle Aged; Prognosis; Retreatment; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome	2019

Article

Year

A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:10

Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Everolimus; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Sirolimus; Tissue Distribution

2012

Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 04-01, Volume: 25, Issue:7

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Renal Cell; Everolimus; Female; Humans; Hydroxychloroquine; Kidney Neoplasms; Male; Middle Aged; Prognosis; Retreatment; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome

2019

Other Studies

1 other study(ies) available for hydroxychloroquine and everolimus

Article	Year
Hydroxychloroquine Destabilizes Phospho-S6 in Human Renal Carcinoma Cells. PloS one, 2015, Volume: 10, Issue:7 Topics: Antineoplastic Agents; Apoptosis; Autophagy; Bortezomib; Cell Line, Tumor; Cell Proliferation; Epithelial Cells; Everolimus; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Hydroxychloroquine; Kidney; Mitochondria; Oxygen Consumption; Proteasome Endopeptidase Complex; Ribosomal Protein S6 Kinases; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; TOR Serine-Threonine Kinases	2015

Article

Year

Hydroxychloroquine Destabilizes Phospho-S6 in Human Renal Carcinoma Cells.

PloS one, 2015, Volume: 10, Issue:7

Topics: Antineoplastic Agents; Apoptosis; Autophagy; Bortezomib; Cell Line, Tumor; Cell Proliferation; Epithelial Cells; Everolimus; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Hydroxychloroquine; Kidney; Mitochondria; Oxygen Consumption; Proteasome Endopeptidase Complex; Ribosomal Protein S6 Kinases; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; TOR Serine-Threonine Kinases

2015